JP2024522163A5 - - Google Patents

Info

Publication number
JP2024522163A5
JP2024522163A5 JP2023575488A JP2023575488A JP2024522163A5 JP 2024522163 A5 JP2024522163 A5 JP 2024522163A5 JP 2023575488 A JP2023575488 A JP 2023575488A JP 2023575488 A JP2023575488 A JP 2023575488A JP 2024522163 A5 JP2024522163 A5 JP 2024522163A5
Authority
JP
Japan
Prior art keywords
composition according
disease
activator
disorder
subject requiring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032674 external-priority patent/WO2022261207A1/en
Publication of JP2024522163A publication Critical patent/JP2024522163A/ja
Publication of JP2024522163A5 publication Critical patent/JP2024522163A5/ja
Pending legal-status Critical Current

Links

JP2023575488A 2021-06-08 2022-06-08 シアル酸結合リガンドを含む新規の粒子組成物 Pending JP2024522163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208150P 2021-06-08 2021-06-08
US63/208,150 2021-06-08
PCT/US2022/032674 WO2022261207A1 (en) 2021-06-08 2022-06-08 Novel particle composition comprising sialic acid binding ligand

Publications (2)

Publication Number Publication Date
JP2024522163A JP2024522163A (ja) 2024-06-11
JP2024522163A5 true JP2024522163A5 (enExample) 2025-06-17

Family

ID=84426331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575488A Pending JP2024522163A (ja) 2021-06-08 2022-06-08 シアル酸結合リガンドを含む新規の粒子組成物

Country Status (7)

Country Link
US (1) US20240358653A1 (enExample)
EP (1) EP4351520A4 (enExample)
JP (1) JP2024522163A (enExample)
CN (1) CN117750946A (enExample)
AU (1) AU2022289003A1 (enExample)
CA (1) CA3221371A1 (enExample)
WO (1) WO2022261207A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118178673B (zh) * 2024-04-07 2024-11-05 铭畅生物医药南通有限公司 一种唾液酸酯环糊精包合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196280A1 (en) * 2006-06-08 2010-08-05 Katrin Claudia Fischer Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications
WO2008039920A2 (en) * 2006-09-27 2008-04-03 Board Of Regents, The University Of Texas System Temperature-sensitive nanoparticles for controlled drug delivery
US20100009007A1 (en) * 2008-07-10 2010-01-14 Baxter International Inc. Non-covalent modification of microparticles and process of preparing same
EP2366386A4 (en) * 2008-10-28 2013-11-27 Univ Santiago Compostela NANOTEHTIC SYSTEMS MANUFACTURED FROM ANIONIC POLYMERS
GB0922066D0 (en) * 2009-12-17 2010-02-03 Univ Belfast Modulator
US9241913B2 (en) * 2011-05-19 2016-01-26 Syracuse University Polysialic acid-based N-trimethyl chitosan gel nanoparticles for systemic drug delivery
ES2711669A1 (es) * 2017-11-02 2019-05-06 Univ Santiago Compostela Sistemas de liberacion de farmacos de acido polisialico y metodos
AU2020283956A1 (en) * 2019-05-28 2021-12-16 Cytodigm, Inc. Microparticles and nanoparticles having sulfate groups on the surface

Similar Documents

Publication Publication Date Title
JP2023541432A5 (enExample)
JP2023041862A5 (enExample)
JP2022009090A5 (enExample)
JP2020033360A5 (enExample)
JP2023519965A5 (enExample)
JP2020509024A5 (enExample)
JP2020117553A5 (enExample)
JP2002508397A5 (enExample)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2017506624A5 (enExample)
JP2018507243A5 (enExample)
JP2023535744A5 (enExample)
IL320452A (en) Combination therapy for prostate cancer
JP2025509510A5 (enExample)
JP2024530189A5 (enExample)
Librodo et al. Chronotherapeutic drug delivery
JP2021509395A5 (enExample)
JP2024517085A5 (enExample)
JP2016505050A5 (enExample)
JP2021505669A5 (enExample)
CN105682671A (zh) 用于管理癌症和治疗癌症并存病的方法
JP2025511402A5 (enExample)
JP2019535830A5 (enExample)
JP2023539154A5 (enExample)
JP2024531799A5 (enExample)